NCT05803850View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

February 27, 2024

Study Completion Date

March 8, 2024

Conditions
IPF
Interventions
DRUG

HNC1058 Capsules

HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.

Trial Locations (1)

33136

Syneos Health, Miami

All Listed Sponsors
lead

Guangzhou Henovcom Bioscience Co. Ltd.

INDUSTRY